Drugs / VXB-241
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07295028 | Nov 2025 → Apr 2026 overdue | lower respiratory tract disorder | Sanofi | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06556147 | Aug 2024 → Feb 2025 overdue | — | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXB-241 | “VXB-241 medium dose, single, IM injection.” NCT07295028 ↗ |
| Modality | Vaccine | “a bivalent vaccine, VXB-241” PMID 40674411 ↗ Jul 2025 |
| Route | Intramuscular | “VXB-241 low dose, single, IM injection.” NCT06556147 ↗ |